1.59
前日終値:
$1.58
開ける:
$1.58
24時間の取引高:
1.62M
Relative Volume:
7.18
時価総額:
$158.88M
収益:
$17.85M
当期純損益:
$-96.93M
株価収益率:
-0.6428
EPS:
-2.4735
ネットキャッシュフロー:
$-88.29M
1週間 パフォーマンス:
+21.37%
1か月 パフォーマンス:
-48.38%
6か月 パフォーマンス:
-66.88%
1年 パフォーマンス:
-79.46%
Nyxoah Sa Stock (NYXH) Company Profile
Compare NYXH vs ISRG, BDX, ALC, MDLN, RMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NYXH
Nyxoah Sa
|
1.59 | 154.89M | 17.85M | -96.93M | -88.29M | -2.4735 |
|
ISRG
Intuitive Surgical Inc
|
402.18 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
|
BDX
Becton Dickinson Co
|
141.61 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
64.14 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
36.42 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
RMD
Resmed Inc
|
186.29 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-07-31 | 開始されました | H.C. Wainwright | Buy |
| 2023-07-19 | 開始されました | Robert W. Baird | Neutral |
| 2022-04-21 | 開始されました | Oppenheimer | Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Peer Perform |
| 2021-12-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-07-28 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Nyxoah Sa (NYXH) 最新ニュース
Nyxoah’s Genio® Wins Prix Galien UK 2026 Award for Best Medical Technology - GlobeNewswire
Nyxoah Updates Capital Structure After Major Share Issuance - The Globe and Mail
Nyxoah SA (NYXH) may report negative earnings: Know the trend ahead of next week's release - MSN
Nyxoah (NASDAQ: NYXH) adds 55,232,558 new shares after US offering - Stock Titan
Cochlear (NYXH) reports 5.91% beneficial ownership in Nyxoah - Stock Titan
Nyxoah closes underwritten public offering - Medical Buyer
Nyxoah Raises $95 Million Through Public Stock Offering in the United States - Idéal Investisseur
Nyxoah issues 55.2M new shares after US public offering, raising total voting shares to nearly 100M. - Pluang
Nyxoah issues 55.2M new shares, boosting total voting rights to nearly 100M. - Pluang
Information on the total number of voting rights and shares - GlobeNewswire
Nyxoah raises $110 million to fund U.S. expansion of sleep apnea device - Investing.com
$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch - The Manila Times
Nyxoah Announces Closing of Underwritten Public Offering - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Nyxoah Shares Slide 3.6% as Stock Approaches Key Support Level (NYXH)CTA Positioning - newsline.com
Nyxoah Launches $88.5 Million Underwritten Share Offering to Fund Genio OSA Expansion - The Globe and Mail
What's Going On With Nyxoah Stock Tuesday? - Benzinga
Nyxoah (NASDAQ: NYXH) raises $95M in U.S. share sale - Stock Titan
Nyxoah (NASDAQ: NYXH) raises ~$95M via 55.2M-share offering - Stock Titan
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering - marketscreener.com
Nyxoah 55.23M share Spot Secondary priced at $1.72 - TipRanks
Sleep apnea device firm Nyxoah prices $95M stock sale for U.S. push - Stock Titan
Nyxoah Begins Search for New US-based CEO - Moomoo
Nyxoah announces proposed offering of ordinary shares - Medical Buyer
Nyxoah announces offering of ordinary shares, no amount given - TipRanks
Nyxoah Launches U.S. CEO Search as Cash Runway Narrows and Patent Fight with Inspire Escalates - TipRanks
Nyxoah SA (NYXH) Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost Discipline Amid Pre-Revenue StageTax Rate Impact - newsline.com
Nyxoah (NYXH) files prospectus supplement for share offering, 30-day overallotment - Stock Titan
Nyxoah Enters New Chapter of Long Term Value Creation - The Manila Times
Nyxoah (NASDAQ: NYXH) outlines US growth, patent fight and cash runway - Stock Titan
Nyxoah Announces Proposed Offering of Ordinary Shares - marketscreener.com
NYXH Q1 2026 Earnings: Beat on EPS Despite No Revenue ReportedWeak Earnings Momentum - newsline.com
Nyxoah SA (NYXH) Gains Ground: Testing Key Resistance LevelsVolatility Term Structure - newsline.com
Nyxoah (NYXH) Slips 5.9% as Shares Test Support Near $2.56Factor Momentum - The Legal Advocate
Nyxoah (NYXH) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances Sleep Apnea PipelineEarnings Trend Analysis - The Legal Advocate
Nyxoah SA (NYXH) Q1 2026 Earnings: Narrower-Than-Expected Loss as Company Advances Sleep Apnea PlatformProfitability Analysis - The Legal Advocate
Nyxoah Q1 earnings call highlights - MSN
Nyxoah SA Q1 2026 Earnings: Narrower-Than-Expected Loss on Operational DisciplineEstimate Dispersion - The Legal Advocate
Nyxoah Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Continued ProgressFinal Results - Newser
Nyxoah SA (NYXH) Stock Analysis: Flat at $2.90, What's Next 2026-05-21Linear Regression - Newser
Nyxoah SA (NYXH) Delivers Q1 2026 Beat — EPS $-0.37 vs $-0.51 ExpectedTrending Volume Leaders - Newser
Nyxoah details 44.7m voting shares, up to 8.6m via bonds - Stock Titan
Nyxoah Welcomes the Flemish Investors Federation (VFB) at - GlobeNewswire
Nyxoah SA Earnings Call Highlights Growth And Strain - TipRanks
Nyxoah SA (NYXH) Fell -3.92% — Is a Recovery Ahead? 2026-05-19Bear Flag - Newser
Nyxoah SA (NYXH) Stock: Slides -4.10%, Support at $2.67 2026-05-19Composite Profile - Newser
Nyxoah Sa (NYXH) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):